Designer steroids: Past, present and future

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 3, 2006, Pages 306-309

  Fourcroy, Jean ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE   (United States)

Author keywords

Anabolic steroids; Designer steroids; Doping; Tetrahydrogestrinone

Indexed keywords

ANABOLIC AGENT; ANDARINE; ANDROGEN; ANDROGEN RECEPTOR; ANDROL 50; BMS 564929; BOLDENONE; BOLDENONE UNDECENOATE; DROSTANOLONE; DROSTANOLONE PROPIONATE; EQUI GAN; ETHYLESTRENOL; FLUOXYMESTERONE; HYDANTOIN; ILLICIT DRUG; KGD 2226; METANDIENONE; METENOLONE ACETATE; METENOLONE ENANTATE; METHYLTESTOSTERONE; NANDROLONE DECANOATE; NANDROLONE LAURATE; OSTARINE; OXANDROLONE; OXYMETHOLONE; PROPIONIC ACID DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; S 40503; STANOZOLOL; STEROID; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; ULTRADREN; UNCLASSIFIED DRUG;

ATHLETE; DOPING; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; PATIENT CARE; REVIEW;

EID: 33646690512     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000224812.46942.c3     Document Type: Review

References (37)

1. Kochakian CD. The evolution from 'the male hormone' to anabolic-androgenic steroids. Ala J Med Sci 1988; 25:96-102.
2. Kochakian CD. How it was: anabolic action of steroids and remembrances. Birmingham: University of Alabama School of Medicine; 1984.
3. Corner GW. The male hormone. In: The hormones in human reproduction. Princeton: Princeton University Press; 1943. pp. 217-223.
4. Freeman ER, Bloom DA, McGuire EJ. A brief history of testosterone. J Urol 2001; 165:371-373.
5. Goetz CG. Battle of the titans: Charcot and Brown-Sequard on cerebral localization. Neurology 2000; 54:1840-1847.
6. Schultheiss D, Denil J, Jonas U. Rejuvenation in the early 20th century. Andrologia 1997; 29:351-355.
7. Hoberman JM, Yesalis CE. The history of synthetic testosterone. Sci Am 1995; 272:76-81.
8. Findlay JC, Place VA, Sybder PJ. Transderlmal delivery of testosterone. J Clin Endocrinol Metab 1987; 63:286-289.
9. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. Adv Intern Med 1991; 36:399-424.
10. Duchaine D. American steroids both oral and injectable. In: Underground steroid handbook (II) update. Marina Del Rey: Power Distributors; 1992. pp. 16-18.
11. Freed DL, Banks AJ, Longson D, Burley DM. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. Br Med J 1975; 2:471-473.
12. Johnson LC, O'Shea JP. Anabolic steroids: effects on strength development. Science 1969; 164:957-959.
13. Marshall E. The drug of champions. Science 1988; 242:L183-L184.
14. Rogol AD, Yesalis CE. Anabolic androgenic steroids and athletes: what are the issues? J Clin Endocrinol Metab 1992; 74:465-469.
15. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988; 9:181-199.
16. Wilson JD, Griffin JE. The use and abuse of androgens. Metabolism 1980; 29:1278-1295.
17. Yesalis CE, editor. Anabolic steroids in sport and exercise. Champaign: Human Kinetics; 1993.
18. Dickman S. East Germany: science in the diservice of the state. Science 1991; 254:24-27.
19. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997; 43:1262-1279.
20. Kammerer RC. What is doping and how is it detected? In: Wilson W, Derse E, editors. Doping in elite sport: the politics of drugs in the Olympic movement. Champaign: Human Kinetics; 2001. pp. 3-28.
21. Todd J, Todd T. Significant events in the history of drug testing and the Olympic movement 1960-1999. In: Wilson W, Derse E, editors. Doping in elite sport: the politics of drugs in the Olympic movement. Champaign: Human Kinetics; 2001. pp. 65-128.
22. Bowers LD. Athletic drug testing. Clin Sports Med 1998; 17:299-318.
23. Catlin DH, Hatton CK, Starcevic SH. Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Clin Chem 1977; 43:1280-1288.
24. Ashley S. Doping by design. Sci Am 2004; 290:22-23.
25. Knight J. Drugs bust reveals athletes' secret steroid. Nature 2003; 425:752.
26. Sekera MH, Ahrens BD, Chang YC. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Commun Mass Spectrom 2005; 19:781-784. This is an important review of the process of discovery of THG.
27. Death AK, McGrath KC, Kazlauskas R, Handelsman DJ. Tetrahydrogestrinone is a potent androgen and progestin. J Clin Endocrinol Metab 2004; 89:2498-2500.
28. Handelsman DJ. Designer androgens in sport: when too much is never enough. Sci STKE 2004; 2004 (244):pe41.
29. Jasuja R, Catlin DH, Miller A, et al. Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. Endocrinology 2000; 146:4472-4478.
30. Labrie F, Luu-The V, Calvo E, et al. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinology 2005; 184:427-433.
31. Brown TR. Nonsteroidal selective androgen receptors modulators (SARMs): designer androgens with flexible structures provide clinical promise. Endocrinology 2004; 145:5417-5419.
32. Marhefka CA, Gao W, Chung K, et al. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem 2004; 47:993-998.
33. Chen JM, Kim J, Dalton JT. Discovery and therapeutic promise. Selective androgen receptor modulators. Mol Interv 2005; 5:173-188. This is an excellent overview of the current development of SARMs.
34. Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005; 146:4887-4897.
35. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endrocrinol Metab 1999; 84:3459-3462.
36. Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskeletal Neuron Interact 2002; 2:222-224.
37. Yin D, Gao W, Kearbey JD, Xu H. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003; 304:1334-1340.